Síndrome Guillain-Barré: Un mirada actual
##plugins.themes.bootstrap3.article.sidebar##
PDF
FLIP
HTML
##plugins.themes.bootstrap3.article.main##
El Síndrome de Guillain-Barré es la causa más frecuente de parálisis flácida aguda no traumática en el mundo y constituye una emergencia neurológica. Consiste en una poliradiculoneuropatia inflamatoria adquirida, usualmente post-infecciosa que se caracteriza por una parálisis aguda arreflexica, generalmente simétrica de carácter ascendente con compromiso sensitivo, motor o mixto. El diagnóstico es clínico, se apoya en el estudio electrofisiológico confirmando el patrón desmielinizante, las anormalidades en la inda F y reflejo H junto con la característica disociación albumino citológica en el líquido cefalorraquídeo.
Descargas
##plugins.themes.bootstrap3.article.details##
Guillain G BJ, Strohl A. Sur un syndrome de radiculonevrite avec hyperalbuminose du liquide cephalorachidien sans reaction cellilaire. Remarques sur les caracteres cliniques et graphiques des reflexes tendineux.Bull Soc Med Hop Paris. 1916;1462–70.
Dimachkie MM, Barohn RJ. Guillain-Barre syndrome and variants. Neurologic clinics. 2013;31(2):491-510.
Van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome.
The Lancet Neurology. 2008;7(10):939-50.
Van Den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, Van Doorn PA. Guillain-Barre syndrome:pathogenesis, diagnosis, treatment and prognosis. Nature reviews Neurology. 2014;10(8):469-82.
Chio A, Cocito D, Leone M, Giordana MT, Mora G, Mutani R. Guillain-Barre syndrome: a prospective, population-based incidence and outcome survey. Neurology. 2003;60(7):1146-50.
Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barre syndrome. The Journal of infectious
diseases. 1997;176 Suppl 2:S92-8.
Alter M. The epidemiology of Guillain-Barre syndrome. Annals of neurology. 1990;27 Suppl:S7-12.
Mcgrogan A, MADLE GC, SEAMAN HE, DE VRIES CS. The epidemiology of Guillain-Barre syndrome worldwide.
A systematic literature review. Neuroepidemiology. 2009;32(2):150-63.
B urns TM. Guillain-Barre syndrome. Seminars in neurology. 2008;28(2):152-67.
Jacobs BC, Rothbarth PH, Van Der Meche FG, Herbrink P, Schmitz PI, De Klerk MA, ET AL. The spectrum of
antecedent infections in Guillain-Barre syndrome: a casecontrol study. Neurology. 1998;51(4):1110-5.
Visser LH, Van Der Meche FG, Meulstee J, Rothbarth PP, Jacobs BC, Schmitz PI, et al. Cytomegalovirus infection
and Guillain-Barre syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barre Study Group. Neurology. 1996;47(3):668-73.
Santos NQ, Azoubel AC, Lopes AA, Costa G, Bacellar A. Guillain-Barre syndrome in the course of dengue:
case report. Arquivos de neuro-psiquiatria. 2004; 62(1):144-6.
Chen TY, Lee CT. Guillain-Barre syndrome following dengue fever. Annals of emergency medicine. 2007;50(1):94-5.
Esack A, Teelucksingh S, Singh N. The Guillain-Barre syndrome following dengue fever. The West Indian medical journal. 1999;48(1):36-7.
Musso D, Cao-Lormeau VM, Gubler DJ. Zika virus: following the path of dengue and chikungunya? Lancet (London, England). 2015;386(9990):243-4.
Cao-Lormeau VM, Blake A, Mons S, Lastere S, Roche C, Vanhomwegen J, ET AL. Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet (London,England). 2016;387(10027):1531-9.
Smith DW, Mackenzie J. Zika virus and Guillain-Barre syndrome: another viral cause to add to the list. Lancet
(London, England). 2016;387(10027):1486-8.
Solomon T, Baylis M, Brown D. Zika virus and neurological disease-approaches to the unknown. The Lancet Infectious diseases. 2016;16(4):402-4.
Villamil-Gómez W, Silvera LA, Paez-Castellanos J, Rodriguez-Morales AJ. Guillain-Barre syndrome after Chikungunya infection: A case in Colombia. Enfermedades infecciosas y microbiología clínica. 2016;34(2):140-1.
Oehler E, Fournier E, Leparc-Goffart I, Larre P, Cubizolle S, Sookhareea C, ET AL. Increase in cases of Guillain-Barre syndrome during a Chikungunya outbreak, French Polynesia, 2014 to 2015. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2015;20(48):30079.
Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, ET AL. Guillain-
Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976—1977. American journal of epidemiology. 1979;110(2):105-23.
Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D, ET AL. The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines. The New England journal of medicine. 1998;339(25):1797-802.
Hughes RA, Charlton J, Latinovic R, Gulliford MC. No association between immunization and Guillain-Barre
syndrome in the United Kingdom, 1992 to 2000. Archives of internal medicine. 2006;166(12):1301-4.
Salmon DA, Proschan M, Forshee R, Gargiullo P, Bleser W, Burwen DR, et al. Association between Guillain-Barre
syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet
(London, England). 2013;381(9876):1461-8.
Gong Y, Tagawa Y, Lunn MP, Laroy W, Heffer-Lauc M, Li CY, et al. Localization of major gangliosides in the PNS:
implications for immune neuropathies. Brain : a journal of neurology. 2002;125(Pt 11):2491-506.
Kusunoki S, Kaida K, Ueda M. Antibodies against gangliosides and ganglioside complexes in Guillain-Barre syndrome: new aspects of research. Biochimica et biophysica acta. 2008;1780(3):441-4.
Kusunoki S, Iwamori M, Chiba A, Hitoshi S, Arita M, Kanazawa I. GM1b is a new member of antigen for serum antibody in Guillain-Barre syndrome. Neurology.1996;47(1):237-42.
Kusunoki S, Mashiko H, Mochizuki N, Chiba A, Arita M, Hitoshi S, ET AL. Binding of antibodies against GM1 and GD1b in human peripheral nerve. Muscle & nerve. 1997;20(7):840-5.
Jacobs BC, Endtz H, Van Der Meche FG, Hazenberg MP, Achtereekte HA, Van Doorn PA. Serum anti-GQ1b
IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome. Annals of Neurology.1995;37(2):260-4.
Jacobs BC, Koga M, Van Rijs W, Geleijns K, Van Doorn PA, Willison HJ, et al. Subclass IgG to motor gangliosides
related to infection and clinical course in Guillain-Barre syndrome. Journal of neuroimmunology. 2008;194(1-2):181-90.
Yuki N, Taki T, Handa S. Antibody to GalNAc-GD1a and GalNAc-GM1b in Guillain-Barre syndrome subsequent to Campylobacter jejuni enteritis. Journal of neuroimmunology. 1996;71(1-2):155-61.
Yuki N, Ho TW, Tagawa Y, Koga M, Li CY, Hirata K, et al. Autoantibodies to GM1b and GalNAc-GD1a: relationship to Campylobacter jejuni infection and acute motor axonal neuropathy in China. Journal of the neurological sciences. 1999;164(2):134-8.
Yuki N. Infectious origins of, and molecular mimicry in, Guillain-Barre and Fisher syndromes. The Lancet Infectious diseases. 2001;1(1):29-37.
Yuki N, Sato S, Tsuji S, Ohsawa T, Miyatake T. Frequent presence of anti-GQ1b antibody in Fisher’s syndrome. Neurology. 1993;43(2):414-7.
Yuki N, Sato S, Tsuji S, Hozumi I, Miyatake T. An immunologic abnormality common to Bickerstaff’s brain stem encephalitis and Fisher’s syndrome. Journal of the neurological sciences. 1993;118(1):83-7.
Hughes RA, Hadden RD, Gregson NA, Smith KJ.Pathogenesis of Guillain-Barre syndrome. Journal of neuroimmunology. 1999;100(1-2):74-97.
Fujimura H. The Guillain-Barre syndrome. Handbook of clinical neurology. 2013;115:383-402.
Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine. 1969;48(3):173-215.
Prineas JW. Pathology of the Guillain-Barre syndrome. Annals of neurology. 1981;9 Suppl:6-19.
Willison HJ, Jacobs BC, Van Doorn PA. Guillain-Barre syndrome. Lancet (London, England). 2016;388(10045):717-27.
Arcila-Londono X, Lewis RA. Guillain-Barre syndrome. Seminars in neurology. 2012;32(3):179-86.
Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Annals of neurology. 1990;27 Suppl:S21-4.
Fokke C, Van Den Berg B, Drenthen J, Walgaard C, Van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria. Brain : a journal of neurology. 2014;137(Pt 1):33-43.
Yuki N, Hartung HP. Guillain-Barre syndrome. The New England journal of medicine. 2012;366(24):2294-304.
Walgaard C, Lingsma HF, Ruts L, Drenthen J, Van Konings Veld R, GARSSEN MJ, ET AL. Prediction of respiratory
insufficiency in Guillain-Barre syndrome. Annals of neurology. 2010;67(6):781-7.
Plasmapheresis and Acute Guillain-Barre Syndrome. The Guillain-Barre syndrome Study Group. Neurology. 1985;35(8):1096-104.
Efficiency of Plasma Exchange in Guillain-Barre syndrome: Role of Replacement Fluids. French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Annals of neurology. 1987;22(6):753-61.
Schroder A, Linker RA, Gold R. Plasmapheresis for neurological disorders. Expert review of neurotherapeutics. 2009;9(9):1331-9.
Kleyweg RP, Van Der Meche FG, Meulstee J. Treatment of Guillain-Barre syndrome with high-dose gammaglobulin. Neurology. 1988;38(10):1639-41.
Van Der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. The New England journal of medicine. 1992;326(17):1123-9.
Randomised Trial of Plasma Exchange, Intravenous Immunoglobulin, and Combined Treatments In Guillain-Barre syndrome. Plasma Exchange/Sandoglobulin Guillain-Barre syndrome Trial Group. Lancet (London,England). 1997;349(9047):225-30.
Hughes RA, Van Doorn PA. Corticosteroids for Guillain-Barre syndrome. The Cochrane database of systematic reviews. 2012(8):Cd001446.
Van Koningsveld R, Schmitz PI, Meche FG, Visser LH, Meulstee J, Van Doorn PA. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet (London, England). 2004; 363(9404):192-6.
Hughes RA, Pritchard J, Hadden RD. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barre syndrome. The Cochrane database of systematic reviews. 2013(2):Cd008630.
Netto AB, Taly AB, Kulkarni GB, Rao UG, Rao S. Mortality in mechanically ventilated patients of Guillain Barre syndrome. Annals of Indian Academy of Neurology. 2011;14(4):262-6.
Van Den Berg B, Bunschoten C, Van Doorn PA, Jacobs BC. Mortality in Guillain-Barre syndrome. Neurology. 2013;80(18):1650-4.
Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barre syndrome in south east England. Journal of neurology, neurosurgery, and psychiatry. 1998;64(1):74-7.
Visser LH, Schmitz PI, Meulstee J, Van Doorn PA, Van Der Meche FG. Prognostic factors of Guillain-Barre syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barre Study Group. Neurology. 1999;53(3):598-604.
Rajabally YA, Uncini A. Outcome and its predictors in Guillain-Barre syndrome. Journal of neurology, neurosurgery, and psychiatry. 2012;83(7):711-8.
González-Suárez I, Sanz-Gallego I, Rodríguez de Rivera FJ, Arpa J. Guillain-Barre syndrome: natural history and prognostic factors: a retrospective review of 106 cases. BMC neurology. 2013;13:95.
Fourrier F, Robriquet L, Hurtevent JF, Spagnolo S. A simple functional marker to predict the need for prolonged mechanical ventilation in patients with Guillain-Barre syndrome. Critical care (London, England). 2011;15(1):R65.
Van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, Van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barre syndrome. The Lancet Neurology. 2007;6(7):589-94.
Garssen MP, Van Koningsveld R, Van Doorn PA. Residual fatigue is independent of antecedent events and disease severity in Guillain-Barre syndrome. Journal of neurology. 2006;253(9):1143-6.
